Concordant morphologic and gene expression data show that a vaccine halts HER-2/neu preneoplastic lesions.
暂无分享,去创建一个
Piero Musiani | Remo Sanges | Federica Cavallo | Manuela Iezzi | Stefania Lanzardo | Raffaele Calogero | Guido Forni | Michela Spadaro | P. Musiani | P. Lollini | G. Forni | R. Sanges | M. Iezzi | R. Calogero | C. De Giovanni | S. Lanzardo | P. De Luca | S. Crispi | F. Cavallo | M. Spadaro | Carla De Giovanni | Elena Quaglino | Simona Rolla | E. Quaglino | Pier Luigi Lollini | Stefania Crispi | Pasquale De Luca | S. Rolla
[1] D. Botstein,et al. Cluster analysis and display of genome-wide expression patterns. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[2] P. Lollini,et al. Systemic effects of cytokines released by gene‐transduced tumor cells: Marked hyperplasia induced in small bowel by γ‐interferon transfectants through host lymphocytes , 1995, International journal of cancer.
[3] T. Blankenstein,et al. B cells inhibit induction of T cell-dependent tumor immunity , 1998, Nature Medicine.
[4] M. Ashburner,et al. Gene Ontology: tool for the unification of biology , 2000, Nature Genetics.
[5] A. Villa,et al. Early and multifocal tumors in breast, salivary, harderian and epididymal tissues developed in MMTY-Neu transgenic mice. , 1992, Cancer letters.
[6] Richard D. DeVeaux. Statistical Factor Analysis and Related Methods , 1996 .
[7] P. Musiani,et al. Inhibition of tumor growth and enhancement of metastasis after transfection of the γ‐interferon gene , 1993 .
[8] Yosef Yarden,et al. A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors , 1997, Oncogene.
[9] P. Lollini,et al. Cancer immunoprevention: tracking down persistent tumor antigens. , 2003, Trends in immunology.
[10] Piero Musiani,et al. DNA Vaccination Against Rat Her-2/Neu p185 More Effectively Inhibits Carcinogenesis Than Transplantable Carcinomas in Transgenic BALB/c Mice1 2 , 2000, The Journal of Immunology.
[11] L. Samelson,et al. LAT The ZAP-70 Tyrosine Kinase Substrate that Links T Cell Receptor to Cellular Activation , 1998, Cell.
[12] R. Ward,et al. Anti-ErbB-2 monoclonal antibodies and ErbB-2-directed vaccines , 2001, Cancer Immunology, Immunotherapy.
[13] Joshua M. Stuart,et al. MICROARRAY EXPERIMENTS : APPLICATION TO SPORULATION TIME SERIES , 1999 .
[14] M. Rodgers,et al. Definition of family of coronin-related proteins conserved between humans and mice: close genetic linkage between coronin-2 and CD45-associated protein. , 1998, DNA and cell biology.
[15] H. Robinson. Prime boost vaccines power up in people , 2003, Nature Medicine.
[16] Y. Yarden,et al. Signal transduction: Molecular ticket to enter cells , 2002, Nature.
[17] Piero Musiani,et al. Interleukin 12–mediated Prevention of Spontaneous Mammary Adenocarcinomas in Two Lines of Her-2/neu Transgenic Mice , 1998, The Journal of experimental medicine.
[18] T. Speed,et al. Summaries of Affymetrix GeneChip probe level data. , 2003, Nucleic acids research.
[19] Karl Pearson F.R.S.. LIII. On lines and planes of closest fit to systems of points in space , 1901 .
[20] P. Bjorkman,et al. Crystal structure of human FcaRI , 2003 .
[21] Y. Yarden,et al. Advances in Brief Tumor-inhibitory Antibodies to HER-2 / ErbB2 May Act by Recruiting c-Cbl and Enhancing Ubiquitination of HER-21 , 2000 .
[22] P. Leder,et al. Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene , 1988, Cell.
[23] Piero Musiani,et al. Combined Allogeneic Tumor Cell Vaccination and Systemic Interleukin 12 Prevents Mammary Carcinogenesis in HER-2/neu Transgenic Mice , 2001, The Journal of experimental medicine.
[24] W. Gullick. A new model for ductal carcinoma in situ suggests strategies for treatment , 2002, Breast Cancer Research.
[25] B. Everitt,et al. Applied Multivariate Data Analysis. , 1993 .
[26] D. de Jong,et al. The microarray way to tailored cancer treatment , 2002, Nature medicine.
[27] P. Musiani,et al. Insertion of the DNA for the 163–171 peptide of IL1β enables a DNA vaccine encoding p185neu to inhibit mammary carcinogenesis in Her-2/neu transgenic BALB/c mice , 2001, Gene Therapy.
[28] Nir Friedman,et al. Practical approaches to analyzing results of microarray experiments. , 2002, American journal of respiratory cell and molecular biology.
[29] R. Calogero,et al. Microarray data analysis and mining. , 2004, Methods in molecular medicine.
[30] P. Musiani,et al. LAG-3 enables DNA vaccination to persistently prevent mammary carcinogenesis in HER-2/neu transgenic BALB/c mice. , 2003, Cancer research.
[31] Nina Bhardwaj,et al. Consequences of cell death: exposure to necrotic tumor cells , 2000 .
[32] R. Tibshirani,et al. Significance analysis of microarrays applied to the ionizing radiation response , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[33] A. Ramsay,et al. The prime-boost strategy: exciting prospects for improved vaccination. , 2000, Immunology today.
[34] P. Musiani,et al. Inhibition of mammary carcinogenesis by systemic interleukin 12 or p185neu DNA vaccination in Her-2/neu transgenic BALB/c mice. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[35] S. E. Brodie. New York, New York, USA , 1996 .
[36] Makoto Katsumata,et al. Prevention of breast tumour development in vivo by downregulation of the p185neureceptor , 1995, Nature Medicine.
[37] H. McShane. Prime-boost immunization strategies for infectious diseases. , 2002, Current opinion in molecular therapeutics.
[38] P. Musiani,et al. Analysis of mammary carcinoma onset and progression in HER-2/neu oncogene transgenic mice reveals a lobular origin. , 1999, Laboratory investigation; a journal of technical methods and pathology.
[39] M. Sliwkowski,et al. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). , 1999, Seminars in oncology.
[40] T. Hunter,et al. Signaling—2000 and Beyond , 2000, Cell.
[41] P. Musiani,et al. Cytokines, tumour-cell death and immunogenicity: a question of choice. , 1997, Immunology today.
[42] P. Musiani,et al. Interleukin 12-activated lymphocytes influence tumor genetic programs. , 2001, Cancer research.
[43] G. Trinchieri,et al. Biology of Natural Killer Cells , 1989, Advances in Immunology.
[44] C. Powers,et al. Midkine Binds to Anaplastic Lymphoma Kinase (ALK) and Acts as a Growth Factor for Different Cell Types* , 2002, The Journal of Biological Chemistry.
[45] P. Musiani,et al. Inhibition of tumor growth and enhancement of metastasis after transfection of the gamma-interferon gene. , 1993, International journal of cancer.
[46] P. Musiani,et al. Immunoprevention of cancer: is the time ripe? , 2000, Cancer research.
[47] J. Miyazaki,et al. Increased Susceptibility to LPS-induced Endotoxin Shock in Secretory Leukoprotease Inhibitor (SLPI)-deficient Mice , 2003, The Journal of experimental medicine.
[48] T. Mcclanahan,et al. HNMP-1: A Novel Hematopoietic and Neural Membrane Protein Differentially Regulated in Neural Development and Injury , 1997, The Journal of Neuroscience.
[49] C. Li,et al. Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. , 2001, Proceedings of the National Academy of Sciences of the United States of America.